$BTSG

ROUSSEAU JON B sold $7.6M of BTSG

ROUSSEAU JON B (See Remarks) sold 130,000 shares of BrightSpring Health Services, Inc. (BTSG) at $58.75 ($7.64M total) on 2026-06-05.

Original reporting
SEC EDGAR · ROUSSEAU JON B
Published Jun 5, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BTSG
Neutral
medium confidence
Mentioned
$BTSG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BTSGNeutralLow
01

Why it matters

The disclosure can modestly affect sentiment and short-term positioning, but it does not constitute new operational guidance, financial results, or deal/regulatory information.

02

Market read

Traders may use the sale as a sentiment input, but it is unlikely to be a standalone catalyst without corroborating fundamental news.

03

What to watch

Track whether additional insiders sell/buy around the same time and whether there are concurrent operational/regulatory updates not captured in this Form 4.

Relevance 6/10Novelty 6/10Timing: Filed same day (2026-06-05) as the sale; relevant for intraday/next-session sentiment checks.

Background

This is an SEC Form 4 insider transaction disclosure (officer/director selling issuer shares).

Company-level read

Ticker impact

$BTSGNeutralMedium confidence
Context

BrightSpring Health Services disclosed an officer/director open-market sale of 130,000 shares at $58.75 on 2026-06-05.

Expected impact

Likely limited/short-lived impact unless follow-on selling or additional disclosures emerge.

Evidence & confidence

Form 4 provides transaction details (size/price) but the filing does not indicate new company-specific news or a 10b5-1 plan.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing; the absence of a 10b5-1 plan does not automatically imply bearish fundamentals.

Key entities

  • BrightSpring Health Services, Inc.

    Subject of the Form 4 insider sale disclosed by an officer/director.

  • ROUSSEAU JON B

    Officer/director who sold 130,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BTSGMedAI 8/10

BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?

BrightSpring Health Services (BTSG) stock has risen 59% YTD, outperforming industry and S&P 500. Q2 2026 revenues grew 23% to $3.9B, adjusted EBITDA up 44%. Growth driven by Specialty Pharmacy and Provider Services, with AI/automation improving efficiency. Leverage reduced to 2.15x. 2026 EPS estimates raised to $1.78 (78% growth). Risks include execution challenges and reimbursement pressures.

$BTSGMedAI 9/10

BrightSpring Health (BTSG) Q2 2026 Earnings Call Transcript

BrightSpring Health Services (BTSG) reported Q2 2026 net revenue of $3.873B, up 23%, and adjusted EBITDA of $205.5M, up 44.2%, with adjusted EPS of $0.45. FY2026 guidance raised to $15.1B-$15.425B revenue and $820M-$845M adjusted EBITDA. Net debt was $1.7B (2.15x leverage).

$BTSGMed

5 Revealing Analyst Questions From BrightSpring Health Services’s Q2 Earnings Call

BrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.

$BTSGMedAI 8/10

BTSG Raises 2026 Guidance as Specialty and Home Health Drive Growth

BrightSpring Health Services (BTSG) beat Q2 expectations with adjusted EPS of 45 cents (21.6% above consensus) and revenue of $3.87B (+23% YoY). It raised 2026 guidance to $15.10-$15.425B revenue and $820-$845M adjusted EBITDA. Specialty and infusion grew 30.1% and home health revenues rose 30.3%, while pharmacy fell 8% due to IRA impacts.